Li Jing, Luo Fei, Zhang Hongtuan, Li Liang, Xu Yong
Department of Urology, Tianjin Key Lab of Urology, Second Affiliated Hospital of Tianjin Medical University, Tianjin, China.
Tumour Biol. 2014 Jan;35(1):171-7. doi: 10.1007/s13277-013-1021-7. Epub 2013 Jul 28.
Published studies on the association between cyclin D1 (CCND1) G870A polymorphism and bladder cancer risk have yielded conflicting results. Thus, a systemic review and meta-analysis of published studies were performed to assess the possible association. All eligible studies of G870A polymorphism and bladder cancer risk were collected from the PubMed and the Cochrane Library. Statistical analyses were performed by Review Manager 5.0 and Stata 11.0. Significant association between G870A polymorphism and bladder cancer susceptibility was found under recessive model in overall population (OR = 1.21, 95% CI 1.01-1.45, P = 0.04). When stratifying for the race, our analysis suggested that CCND1 G870A was associated with bladder cancer risk in Asians when using homogeneous codominant (OR = 1.72, 95% CI 1.34-2.20, P < 0.0001), recessive (OR = 1.46, 95% CI 1.21-1.77, P < 0.0001), dominant (OR = 1.36, 95% CI 1.10-1.69, P = 0.004), and allelic models (OR = 1.30, 95% CI 1.15-1.47, P < 0.0001) to analyze the data. However, no significant associations were found in Caucasians. After stratifying the studies by control source, G870A polymorphism was significantly associated with bladder cancer risk under recessive model (OR = 1.31, 95% CI 1.03-1.67, P = 0.03) in hospital-based case-control studies, but not in population-based case-control studies. This meta-analysis suggested that G870A polymorphism most likely contributes to increased susceptibility to bladder cancer in the overall population, hospital-based case-control studies, and Asians.
关于细胞周期蛋白D1（CCND1）G870A多态性与膀胱癌风险之间关联的已发表研究结果相互矛盾。因此，我们进行了一项已发表研究的系统评价和荟萃分析，以评估可能存在的关联。从PubMed和Cochrane图书馆收集了所有关于G870A多态性与膀胱癌风险的符合条件的研究。使用Review Manager 5.0和Stata 11.0进行统计分析。在总体人群的隐性模型下，发现G870A多态性与膀胱癌易感性之间存在显著关联（OR = 1.21，95%CI 1.01 - 1.45，P = 0.04）。按种族分层时，我们的分析表明，在亚洲人中，使用同质共显性（OR = 1.72，95%CI 1.34 - 2.20，P < 0.0001）、隐性（OR = 1.46，95%CI 1.21 - 1.77，P < 0.0001）、显性（OR = 1.36，95%CI 1.10 - 1.69，P = 0.004）和等位基因模型（OR = 1.30，95%CI 1.15 - 1.47，P < 0.0001）分析数据时，CCND1 G870A与膀胱癌风险相关。然而，在白种人中未发现显著关联。按对照来源对研究进行分层后，在基于医院的病例对照研究中，隐性模型下G870A多态性与膀胱癌风险显著相关（OR = 1.31，95%CI 1.03 - 1.67，P = 0.03），但在基于人群的病例对照研究中并非如此。这项荟萃分析表明，G870A多态性很可能导致总体人群、基于医院的病例对照研究人群以及亚洲人群对膀胱癌的易感性增加。
